Post-traumatic stress disorder (PTSD) is associated with a dysregulation of the hypothalamus-pituitary-adrenal axis (HPA axis). In addition, there is evidence for altered glucocorticoid receptor (GR) expression and function in peripheral blood mononuclear cells. The aim of the present study was to differentiate between the effect of trauma exposure and PTSD on leukocyte GR expression and glucocorticoid immune regulation. Leukocyte GR binding characteristics and glucocorticoid sensitivity of immune activity, determined as the effect of dexamethasone (DEX) on in vitro cytokine release and T-cell proliferation, were compared between veterans with PTSD, traumatized veterans without PTSD and healthy controls. Leukocyte GR density was significantly lower in veterans with and without PTSD compared to healthy controls. DEX-induced inhibition of T-cell proliferation was significantly lower in PTSD compared to trauma and healthy controls. DEX-induced increase in lipopolysaccharidestimulated interleukin-10 was less pronounced in traumatized veterans with and without PTSD compared to healthy controls. No group differences were observed in the effect of DEX on other cytokines or in baseline immune activity, except for lower tumor necrosis factor-a production in PTSD patients compared to healthy controls. The results suggest that trauma exposure is sufficient to induce changes in GR binding characteristics, whereas resistance of T-cell proliferation to DEX only occurs in PTSD. DEX resistance of in vitro immune activity was not a general phenomenon, but was restricted to specific immune functions.
Introduction
There is converging evidence that severe psychological distress or life-threatening events are important risk factors for the development of several psychiatric and non-psychiatric conditions, such as post-traumatic stress disorder (PTSD), major depressive disorder (MDD), cardiovascular disease and chronic fatigue. [1] [2] [3] [4] Several studies have implicated the hypothalamic-pituitary-adrenal axis (HPA axis) as key substrate in the pathogenic processes underlying these disorders. [5] [6] [7] Chronic stress and PTSD are generally thought to cause long-term alterations in the HPA axis regulation. [8] [9] [10] [11] Over the last decade many studies have reported on the activity of the HPA axis in PTSD, but these studies did not always report consistent findings. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Preclinical research has shown that the central nervous system, the endocrine system and the immune system closely interact. 22 Traumatic or chronic stress may therefore have an effect on the regulation of both HPA axis 8, 11 and immune system 23, 24 separately, as well as on their interaction. 25 Cortisol, the end product of HPA axis activation, is thought to be an important endogenous modulator of the immune response. 26 Binding of glucocorticoids (e.g., cortisol) to GRs in immune cells is known to inhibit mitogen-induced lymphocyte proliferation and the production of pro-inflammatory cytokines. The immune modulating effect of glucocorticoids not only depends on the level of circulating cortisol but also on the number and subtypes of GRs in immune cells and on molecular interactions downstream of receptor activation. 27 Some early studies that assessed peripheral blood mononuclear cell (PBMC) GR density and binding affinity in PTSD report higher PBMC GR density in PTSD, 28, 29 but later studies did not replicate these findings. [30] [31] [32] Flow cytometric determination of GR expression in lymphocyte subpopulations even revealed a lower GR expression in all lymphocyte subsets from PTSD patients compared to healthy individuals. 33 To get an indication of GR function in the immune system, the capacity of glucocorticoids to inhibit immune responses in vitro 32, 34 as well as in vivo dexamethasone (DEX)-induced changes in leukocyte GR binding 30, 31 have been measured in PTSD. The aim of the present study was to differentiate between the effect of trauma exposure and PTSD on leukocyte GR binding characteristics and glucocorticoid immune regulation. Leukocyte GR binding characteristics were measured in living cells with increasing doses of radioligand, allowing for accurate determination of GR binding affinity and GR density. To investigate whether the effect of glucocorticoids on specific in vitro activity of the immune system can be used as a general model for GR function, we assessed the effect of DEX on various aspects of the immune response, including DEX inhibition of T-cell proliferation, and T cell and monocyte cytokine secretion in vitro. We determined T-cell mitogen-induced production of IFN-g as a prototype pro-inflammatory Th1-type cytokine and interleukin-10 (IL-10) as an antiinflammatory cytokine. As a measure of DEX effects on innate immunity, we determined changes in lipopolysaccharide (LPS)-induced tumor necrosis factor a, a, pro-inflammatory cytokine that is highly sensitive to DEX inhibition and the anti-inflammatory cytokine IL-10, production of which is inhibited at high doses of DEX and potentiated at low doses of DEX.
In order to investigate the role of trauma and PTSD on these outcome measures, we compared veterans with PTSD with age-, region-and year of deploymentmatched traumatized veterans without PTSD and non-traumatized healthy controls.
Methods
Participants PTSD patients were recruited from the Department of Military Psychiatry at the Central Military Hospital, Utrecht, The Netherlands. Between August 2002 and August 2005, all new male patients diagnosed with PTSD were asked to participate in this study. Trauma controls (TC) were selected from a group of 360 male veterans registered at the Veteran Institute. They were, whenever possible, matched with the PTSD group for age, year and region of deployment. Healthy male controls (HC) were recruited through advertisement and were matched for age. HC were included if there was no indication for a psychiatric disorder according to the Hopkins symptom checklist (SCL-90) and the Dutch Self Inventory for PTSD (ZIL), 35 and no report of traumatic experiences. All veterans were screened for psychiatric illness and history of drug abuse using the Structured Clinical Interview for DSM IV axis I disorders. 36 The diagnosis of PTSD was confirmed by the Clinical Administered PTSD Scale (CAPS) 37 and after consensus by three clinicians (CdK, EV, EG). Only patients with a CAPS score above 50 were included in this study. TC were included if they met the A1 criteria for PTSD, but had a CAPS score below 25 and did not meet DSM IV criteria for PTSD or any other current axis I disorder. None of the included veterans were physically injured during their deployment. At study entry, all participants had to be free of any psychotropic medications and medication that affect the HPA axis, for example glucocorticoids, for at least 4 weeks. Subjects with a serious somatic illness or a psychiatric illness other than mood and anxiety disorders were excluded.
Baseline endocrine and immune measurements as well as GR sensitivity was obtained from all subjects PTSD (n = 29), TC (n = 29), HC (n = 25). Only PTSD patients included between August 2004 and August 2005 were asked to additionally participate in the GR binding study (n = 14) . For this part of the protocol, trauma controls (n = 13) were also matched for age, region and year of deployment and healthy controls (n = 16) were matched for age.
The study was approved by the Ethical Review Board of the University Medical Centre Utrecht, The Netherlands. Written informed consent was obtained from all subjects who participated in the study after a complete written and verbal description of the study.
Blood sampling
Participants were instructed to refrain from coffee, chocolate and fruit intake on the morning of sampling. Blood was collected between 0900 and 0930 in heparinized vacutainers for functional assays and in ethylenediaminetetraacetic acid vacutainers for cortisol and blood count. Plasma for cortisol measurement was stored at À801C. ). Cell-bound radioactivity was determined using a liquid scintillation counter. The number of specific DEX-binding sites per cell (B max ) and the dissociation constant (K d ) were analysed by computer-assisted iterative nonlinear regression curve fitting procedures using Graph Pad Prism 4.02.
GR binding characteristics

Immunemeasures
Cellular composition of peripheral blood. Leukocyte subsets in peripheral blood were assessed using dualcolor fluorescence analysis with a Becton Dickinson Calibur flowcytometer. Whole blood was stained using monoclonal antibodies labeled with either fluorescine isothiocyanate or phyco-erythrin to quantify CD14 þ (monocytes), CD3 þ (total T cells), CD4 þ (T-helper cells), CD8 þ (T suppressor, T cytotoxic) and CD19 þ (B cells). Absolute numbers of cells were calculated from a total leukocyte count.
In vitro response of peripheral blood cells to DEX. The response of peripheral blood cells to DEX was measured using methodology described previously. 40 Diluted blood was cultured with phytohemagglutinin (PHA) (final concentration 25 mg/ml) in the presence or absence of increasing concentrations of DEX (3-1000 nM DEX). After 72 h of culture, 50 ml of supernatant was collected for determination of cytokine levels and 1 mCi (37 kBq) [ 3 H]-thymidine was added. Sixteen to eighteen hours later, cells were harvested by the use of an automated cell harvester, and incorporated radioactivity was determined as a measure of the proliferative response using a liquid scintillation counter. The supernatants were stored at À801C until measurement of IL-10 and IFN-g levels by standard enzyme-linked immunosorbant assay (Sanquin, Amsterdam, The Netherlands).
The effect of DEX on monocyte-derived pro-inflammatory (TNF-a) and anti-inflammatory (IL-10) cytokine production was measured in LPS-stimulated whole-blood cultures in the presence or absence of similarly increasing concentrations of DEX. Supernatants were collected after 18 h of culture and IL-10 and TNF-a concentration were determined.
Plasma cortisol
Cortisol levels were measured using a competitive luminoimmuno-assay (Nichols Advantage). Reference values (8-10 am): 0.19-0.7 mmol/l. All samples were analysed in one batch.
Statistical analysis
The demographics, psychometric scales and baseline immune and endocrine parameters were compared between the three groups. Parametric tests (ANOVA) and post hoc tests (Scheffé) were used when appropriate. Where necessary, a logarithmic transformation was used to normalize the distribution. When normality was not reached, data were analysed using nonparametric tests (Kruskal-Wallis test). Repeated measures analysis was used to measure the effect of DEX on T-cell proliferation and cytokine secretion. When the assumption of sphericity was violated, the degrees of freedom were corrected using Greenhouse-Geisser estimates of sphericity. IC 50 and maximal inhibition were compared between groups using parametric or non-parametric tests depending on the distribution.
A biphasic response to DEX does not allow calculation of IC 50 . In order to analyse the differences in response, we then compared the area under the dose-response curve between groups.
The effect of a comorbid depressive disorder was evaluated by comparing all outcome variables between PTSD patients with and without PTSD. All statistical analyses were carried out using SPSSPCv.11.5. Differences between groups were considered statistically significant at P < 0.05. Data are expressed as mean and standard deviation (s.d.).
Results
Demographics
The demographic characteristics of PTSD patients (n = 29), TC (n = 29) and HC (n = 25) are displayed in Table 1 . Patients and controls did not differ with respect to body mass index or race. Patients with PTSD had significantly higher CAPS, Hamilton A and Hamilton D scores (see Table 1 ). The mean CAPS score in PTSD patients was 76 (range 51-106) and in TC 6 (range 0-18). Lifetime DSM-IV axis I diagnosis are displayed in Table 1 for PTSD patients and TCs. Substance abuse and dependence included cannabis and cocaine. Fourteen PTSD patients also met DSM-IV criteria for a current depressive episode, five patients met current diagnostic criteria for somatoform disorder and one patient met current diagnostic criteria for panic disorder with agoraphobia. Out of 29 patients, 24 were naïve for psychotropic medication. All other patients were medication-free for at least 4 weeks. Fourteen PTSD patients, 13 TCs and 16 HCs were included in the GR binding study. In this subsample, nine PTSD patients were diagnosed with a comorbid MDD. Owing to technical problems, not all samples for PHA-stimulated cytokine measurements were analysed (21 PTSD, 29 TC and 19 HC).
In vitro
3 H-DEX binding to peripheral blood mononuclear cells No significant group difference was observed in the affinity of 
Composition of the leukocyte population
To examine the possibility that the observed group differences in GR binding characteristics were caused by differences in the composition of the leukocyte population in the peripheral blood, we analysed the subset distribution of these cells. Total numbers of leukocytes were all within the normal range (4.0-10.0 Â 10 9 /l) and there was no significant difference between groups (F 2,84 = 0.19; P = 0.19). Moreover, no group differences were observed in total number of lymphocytes, monocytes, B-lymphocytes and T-lymphocytes (total, helper/inducer and T suppressor/ cytotoxic) per milliliter nor in the percentage of T-cell subsets or B cells within the lymphocyte population.
Mitogen-induced cytokine secretion
Before analysing the sensitivity of the immune system to regulation by DEX, we first determined the capacity of peripheral blood cells to proliferate and to release pro-and anti-inflammatory cytokines in response to stimulation with the T-cell mitogen PHA. No significant differences were observed in the proliferative response to PHA stimulation (ANOVA F 2,79 = 2.38, P = 0.10), as well as in PHA-stimulated secretion of IFN-g (ANOVA F 2,67 = 0.70, P = 0.50) and IL-10 (ANO-VA F 2,67 = 0.56, P = 0.57) ( Table 2) .
To evaluate the capacity of monocytes to release cytokines, we stimulated whole-blood cultures with LPS, known to specifically induce cytokine release by monocytes. We observed a significant group difference in LPS-induced TNF-a secretion (ANOVA F 2,84 = 4.21, P = 0.018). Post hoc tests showed that this effect could be attributed to a significantly lower level of TNF-a in cultures from PTSD patients (TNF-a: 7327277 pg/ml) compared to HC (TNF-a: 9987320 pg/ml; Scheffé: P = 0.027). There was no significant difference in LPS-stimulated TNF-a secretion between TC and HC or between PTSD and TC (TNF-a: 9197439 pg/ml). No significant group difference was observed in LPS-stimulated IL-10 levels (ANOVA F 2,80 = 0.03, P = 0.97) ( Table 2 ).
Ex vivo response of peripheral blood cells to DEX To investigate the functional capacity of the GRs in leukocytes, the effect of DEX on mitogen-induced T-cell proliferation and cytokine production was measured. Addition of DEX to cultures stimulated with PHA resulted in a dose-dependent inhibition of the proliferative response (F 1,5; 105 = 219; P < 0.001). The inhibitory effect of DEX was less pronounced in samples from PTSD patients compared to HC (Figure 2 , Table 3 ). There was a significant group difference in the dose of DEX resulting in a 50% 
Abbreviations: BMI, body mass index; CAPS, clinical Administered PTSD Scale; HC, healthy controls; MDD, major depressive disorder; PTSD, post-traumatic stress disorder; TC, trauma controls. Outcome variables were compared between three groups using parametric (ANOVA) or non-parametric tests (Kruskal-Wallis test) depending on the normality of distribution. Variables are displayed as mean, standard deviation (s.d.) and range.
inhibition of T-cell proliferation (IC 50 ) (KruskalWallis test w 2 = 7.41; df = 2; P = 0.025). No significant difference was observed in IC 50 between PTSD and HC or between TC and HC, but PTSD patients showed a higher IC 50 compared to TC (Kruskal-Wallis test w 2 = 6.61; df = 1; P = 0.01) (Figure 2 , Table 3 ). We also observed significant group differences in the inhibition of T-cell proliferation at the highest dose of DEX (1000 nM) (ANOVA: F 2,79 = 4.59; P = 0.01. Inhibition of T-cell proliferation at the highest dose of DEX in PTSD patients was significantly lower in PTSD compared to HC and TC (P = 0.020). No significant differences in maximal effect of DEX (1000 nM) between TC and HC were detected.
Regulation of cytokine secretion by DEX
To investigate whether the alteration in GR function in PTSD reflects a general alteration in GR function or is specific for certain aspects of the immune response, the effect of DEX on cytokine secretion was measured. ;130 = 92.4; P < 0.001) production. However, no significant group differences were observed in IC 50 and maximal DEX inhibition (at 1000 nM DEX) of PHA-stimulated IFN-g and IL-10 release (Figure 3a and b) . LPS-stimulated TNF-a secretion was significantly inhibited by DEX in all groups (repeated measures: F 1,7;143 = 387; P < 0.001). No significant group differences were observed for IC 50 and effect of 1000 nM DEX on LPS-stimulated TNF-a (Figure 3c ). DEX also significantly affected LPS-induced IL-10 secretion. DEX induced an increase in IL-10 secretion at the lower concentrations, with a peak between 20 and 50 nM DEX (repeated measures: F 4,243 = 5.6; P = 0.009), and decreased IL-10 secretion at higher DEX concentrations (repeated measures: F 3,243 = 144; P < 0.001) (Figure 3d ). Repeated measure analysis showed a significant group by dose interaction (F 4,156 = 4.9; P = 0.001). (Figure 3d ). This biphasic dose-response curve for the effect of DEX on IL-10 secretion did not allow calculation of the IC 50 , but significant group differences were observed in area under the curve (AUC) (Kruskal-Wallis test w 2 = 6.6; df = 2; P = 0.04) with significantly lower AUC in PTSD (P = 0.03) and TC (P = 0.02) compared to HC. When comparing LPSstimulated IL-10 increase in response to DEX, DEX induced a maximal increase (33%) at a DEX concentration of 50 nM in HC, whereas DEX induced a maximal increase in PTSD (12%) and TC (15%) at a DEX concentration of 10 nM. No significant group differences were observed in the maximal dose of DEX (1000 nmol/l).
Plasma cortisol
To determine if the observed group differences in GR binding and function could be related to individual differences in plasma cortisol levels, we measured plasma cortisol in the same blood samples. Plasma cortisol levels were within the normal range (0.20-0.65 mmol/l) in all groups. There was no significant group difference in plasma cortisol concentrations (PTSD: 0.4170.11 mmol/l, TC: 0.4170.07 mmol/l, HC: 0.3670.09 mmol/l) (F 2,76 = 2.55; P = 0.08). Analyses of the cortisol levels and the GR binding characteristics showed no correlation between plasma cortisol levels and B max (Pearson: r = À0.070; P = 0.66;) or K d (Pearson: r = À0.23; P = 0.18). In addition, cortisol levels did not correlate with DEX inhibition of proliferation (AUC) (Pearson: r = À0.162; P = 0.15) either.
Comorbid major depressive disorder
Fourteen out of the 29 PTSD patients were diagnosed with a current comorbid depressive disorder. As it has been suggested that depressive disorder may be associated with altered GR sensitivity, we analysed the effect of comorbid depressive disorder on all outcome measures within the PTSD group. No significant differences were observed between PTSD patients with and without comorbid MDD in leukocyte GR density (P = 0.74) and binding affinity (P = 0.19) ( Table 4) . We did not observe differences in PHA-and LPS-stimulated cytokine secretion (P > 0.40) and the effect of DEX on cytokine secretion (P > 0.40) and T-cell proliferation (Table 4) . Cortisol levels were not significantly higher in PTSD with comorbid MDD (0.4470.10 mmol/l) compared to PTSD patients without MDD (0.3870.12 mmol/l, P = 0.13).
Discussion
In this study, we observed a lower leukocyte GR density in traumatized veterans with and without PTSD compared to nontraumatized healthy controls, whereas only veterans with PTSD show a reduced regulation of T-cell proliferation by DEX. The data suggest that some biological alterations are specific for PTSD whereas others are related to traumatic stress during deployment or other military-related factors. Measurement of leukocyte GR expression and sensitivity to DEX can be used to assess glucocorticoid immunoregulation. In addition, these measurements have been used as an easily accessible model to investigate glucocorticoid regulation of the HPA axis in previous studies. [28] [29] [30] However, contradicting data exist as to whether glucocorticoid sensitivity is a characteristic of the individual, for example GR polymorphisms, or is dependent on the target tissue investigated. Some studies described similar regulation of GR in the brain and in the immune system 41, 42 whereas other studies did not observe correlation in GR sensitivity between different target tissues. [43] [44] [45] [46] To characterize leukocyte GR sensitivity in PTSD, we measured the effect of DEX on the mitogeninduced proliferative response and on pro-and antiinflammatory cytokine secretion by PHA-stimulated T cells. Interestingly, the decreased sensitivity to DEX at the level of T-cell proliferation was not reflected in decreased DEX sensitivity of T-cell cytokine production. In addition, we assessed the sensitivity of LPSinduced cytokine production to regulation by DEX as a measure of the sensitivity of the innate immune response to glucocorticoid regulation. In the absence of DEX, the LPS-induced production of TNF-a was reduced in PTSD compared to HC and TC, whereas the response to DEX did not differ between groups. In vitro studies using healthy controls have already shown that the effect of glucocorticoids on monocyte IL-10 secretion, but not on T-cell IL-10 secretion, is biphasic, characterized by stimulation at lower doses and inhibition at higher doses. 47, 48 When comparing groups we observed a less pronounced stimulation of IL-10 at low doses of DEX in LPS-stimulated wholeblood cultures of veterans with and without PTSD compared to HC, indicating a decreased DEX sensitivity. Similarly, to what we observed in the T-cell compartment, the alteration in DEX sensitivity of monocytes in PTSD was limited to certain aspects of the function of these cells and did not reflect a general decreased DEX sensitivity of monocytes. In addition, in the same groups of individuals we have shown that PTSD patients and trauma controls have an increased response to in vivo low-dose DEX suppression of saliva cortisol, which is indicative of increased brain GR sensitivity rather than resistance. 49 Therefore, we conclude that determination of the effect of glucocorticoids on specific in vitro activity of the immune system cannot be used as a general model for GR function in the HPA axis. In view of the complex mechanism of action of GR in immune cells, this is not surprising.
It is known that GR in the immune system act not only via activation or repression of genes with a glucocorticoid response element in the promoter region but also through indirect effects mediated by protein-protein interactions with other transcription factors such as NFkB, NFAT and AP-1. In addition, GR function is determined by GR density, the GR subtype expressed in the cell, the subcellular localization of GR and the efficiency of ligand-induced nuclear translocation of GRs. It is therefore not surprising that we did not observe a direct relation between the number of receptors expressed and the effect of stimulation of these receptors on various immune functions. Our data show that despite a lower GR density in both TC and PTSD, the effect of DEX on production of T-cell cytokines is not altered, suggesting that the interaction of GRs with transcription factors regulating these cytokines is not affected by the lower receptor density. In contrast, there is a specific defect in the effect of DEX on T-cell progression through the cell cycle in patients with PTSD that does not occur in TC who also have a low GR density. The mechanism responsible for this difference remains to be determined, but cannot be attributed to group differences in composition of the peripheral blood mononuclear cell population, plasma cortisol levels at the time of sampling or to differences in basal proliferative capacity in the absence of DEX. In the same population we have measured diurnal salivary cortisol levels (awakening, 30 and 60 min after awakening; noon, 1600 and 2000). 49 Apart from a flattened awakening cortisol response in PTSD patients and trauma controls compared to healthy controls, no differences were observed in diurnal cortisol levels. We cannot exclude that differences in awakening cortisol response contributed to the observed differences in leukocyte GR density.
We suggest that careful delineation of the function and expression of GRs in the immune system by in vitro studies can give important information on the functionality of the GC-immune system axis in vivo and investigation of disturbances in brain-immune communication. For example, a reduced regulation of T-cell proliferation by DEX could contribute to altered regulation of the clonal expansion of T cells that is important in determining the efficacy of the immune response to for example vaccination and infection.
Our results are not consistent with previous studies that showed enhanced DEX sensitivity in PTSD. Rohleder et al. 34 reported no difference in LPSstimulated TNF-a release and a reduction of the IC 50 for LPS-induced TNF-a (and IL-6) suppression by DEX in Bosnian refugees with PTSD compared to HC. In contrast, we report lower LPS-induced TNF-a release in PTSD and no group differences in the effect of DEX on TNF-a. This difference may be due to differences in study design. The production of cytokines by monocytes in the study by Rohleder et al. was induced with 30 ng/ml of LPS and supernatants were harvested after 6 h, whereas we used 2 ng of LPS and a 16-18 h culture period. Finally, we used the actual concentration of cytokines in the culture supernatant for data analysis, whereas Rohleder et al. normalized the cytokine levels for the total number of monocytes present in the cultures. Perhaps more importantly, the two studies differed in type of trauma, gender (mixed group versus only male) and age. For example, female and male Bosnian war refugees with PTSD and a control group consisting of Bosnian refugees (n = 5) and laboratory staff (n = 8) were used by Rohleder et al., whereas we included only male veterans with PTSD (n = 29), male veterans without PTSD (n = 29) and a healthy nonmilitary male control group, recruited by advertisement (n = 25). The veterans in our study were at the time of trauma exposure trained soldiers who were involved in peacekeeping missions outside The Netherlands. Although no details have been reported on the history of the Bosnian refugees, it is likely that there are major differences in physical and psychosocial status at the time of trauma exposure between the veterans in our study and the Bosnian refugees in the study by Rohleder et al.
Yehuda et al. studied GR function in relation to alterations in HPA axis functioning in PTSD. These authors reported increased sensitivity for DEX of peripheral blood leukocytes from PTSD patients when using inhibition of lysozyme activity as a read-out. 32 In contrast to the assays we used to determine glucocorticoid receptor function, in the study by Yehuda et al., cells were not stimulated to perform a certain immune activity, isolated cells (in the absence of endogenous plasma) were used and the culture period was much longer. In another study, 30 the in vivo effect of administration of DEX on the change in GR expression was studied and the data suggest increased GR functioning in PTSD, as oral administration of DEX induced an increased reduction of GR number in peripheral blood mononuclear cells of PTSD patients. 30 Obviously, we cannot directly compare these in vivo effects on receptor availability with in vitro studies on modulation of specific immune functions.
Our finding of a lower leukocyte GR density is in contrast with other studies that reported higher leukocyte GR density in PTSD compared to healthy controls 28, 29 or data by the same group suggesting that there are no differences in GR density between PTSD patients and trauma or healthy controls. [29] [30] [31] Differences in the method used to assess GR density may have contributed to the discrepancy in results between GR binding studies. Yehuda et al. [28] [29] [30] [31] [32] determined GR density in a total cell homogenate of frozen cells, using a binding assay with only one dose of DEX to calculate GR density. In our present study, GR density and binding affinity was measured in living cells using a classical whole-cell binding assay. It may well be possible that during the process of freezing and homogenizing cells, changes in proteinprotein interactions, changes in degree of phosphorylation, protein degradation, changes in the cell membrane or loss of specific cell types may influence the outcome of GR binding studies in specific patient groups. As mentioned above, the studies of Yehuda et al. and our study also differ with respect to the composition of the subject population. For example, our populations consisted completely of Caucasians, whereas in the study of Yehuda et al., 42% of the subjects were African-American.
It remains to be determined whether the apparent discrepancies in the conclusions on the nature of the alterations in leukocyte GR binding and GR function are due to differences in subject characteristics or to differences in the functional read-outs used.
Our data suggest that traumatic stress during deployment may contribute to the altered expression of GR in TC and PTSD. However, we cannot exclude that other factors, associated with deployment and military training, including vaccination, change of environment, physical exercise, chronic stress and military selection may also be responsible for the difference in GR expression levels between veterans and the non-military healthy controls.
Differences in patient characteristics between studies included gender, age, cause of trauma and the time passed since the traumatic event. Preclinical studies have shown that the development of receptor alterations after intense social stress is time-dependent. 50, 51 In a clinical design, significant correlations between the time passed since the traumatic event and in vivo DEX sensitivity have been reported. 52 In line with these observations, it is important to highlight that our results are strengthened by the inclusion of a homogeneous population in type of trauma, moment of trauma in lifespan and the time passed since the traumatic event.
There are some limiting factors that need to be taken into account when interpreting the data. First of all, we did not include a military non-traumatized control group. This would have enabled us to differentiate between the effects of trauma and other military-related factors on leukocyte GR expression and sensitivity. Second, we included PTSD patients with and without a comorbid MDD. Data from epidemiological surveys indicate that the vast majority of individuals with PTSD meet criteria for at least one other psychiatric disorder. 53, 54 The most common comorbid diagnoses are depressive disorder, substance use disorders and other anxiety disorders. As substance disorders are known to influence neurobiology significantly, we have excluded this group. Because of the high rate of comorbid MDD in PTSD, almost half of the patients with PTSD is diagnosed with comorbid MDD, 55 and the large overlap in clinical symptoms between PTSD and MDD, most studies on PTSD do not exclude patients with comorbid MDD, but do analyse the effect of comorbid MDD on outcome measures. Other studies that assessed GR function or GR binding characteristics also included patients with comorbid MDD; therefore, it is not likely that inclusion of patients with comorbid MDD can account for the observed differences between our data and previous studies. As several studies have reported a decreased effect of DEX on T-cell proliferation in MDD 56, 57 it is important to investigate the effect of a comorbid MDD. However, our additional analyses suggest that a comorbid MDD did not cause the observed differences. Third, although early life trauma has been shown to affect HPA axis functioning significantly, 58 and might there-fore also have its effect on glucocorticoid immunoregulation, we did not assess the contribution of early life trauma. In this study, we reported long-lasting alterations in glucocorticoid immune regulation after deployment. Epidemiological research increasingly suggests that exposure to traumatic events is related to adverse health outcomes and the onset of specific diseases. 3, 4, 59 To gain more insight in human adaptation to traumatic stress and the relation of these processes with alterations in GR expression, glucocorticoidimmune interaction and psychopathology, further research in a longitudinal, instead of a cross-sectional design, is preferable.
